Barclays Cuts Rating on Pacira BioSciences Post Generic Exparel Nod
Wednesday, 3 July 2024, 18:32
Barclays Downgrades Pacira BioSciences
Barclays has decided to lower its rating on Pacira BioSciences (PCRX) following the FDA's approval of a generic alternative to Exparel, the company's primary product.
Impact on Company's Best-Selling Drug
The approval of the generic Exparel will directly affect the market shares and revenue of Pacira BioSciences.
Read more to explore the potential implications of this development on PCRX's financial performance and market standing.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.